Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Rezdiffra is used in adults to treat nonalcoholic steatohepatitis (NASH) in certain situations, along with diet and exercise. NASH involves a buildup of fat in your liver that can cause ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal’s MASH treatment Rezdiffra receives EU approvalAnalyst activity has been notable, with Goldman Sachs reiterating a Buy rating and a $567 price target for Madrigal Pharmaceuticals. Piper ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...

Rezdiffra’s Market Performance Rezdiffra has demonstrated strong market acceptance since its launch, with prescription rates steadily increasing. According to recent surveys, the drug’s prescription ...